Opioid Use Disorder Clinical Trial
Official title:
Pilot Feasibility of Night Respite Care for Postpartum Mothers With Substance Use Disorder in Residential Treatment Programs
This single arm pilot feasibility study will evaluate the implementation of overnight infant respite care and parenting skills to mothers with substance use disorders in the early postpartum period residing in residential substance use disorder treatment programs.
Status | Recruiting |
Enrollment | 35 |
Est. completion date | April 30, 2025 |
Est. primary completion date | December 31, 2024 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Caring for an infant under 12 months of age. - Being the primary caretaker for their infant. - Having a DSM-5 diagnosis of a substance use disorder. - Currently residing in a participating residential treatment program or private home setting - English-speaking or Spanish-speakers with limited English proficiency Exclusion Criteria: - Having an untreated serious mental health illness. - Having an untreated substance use disorder or existing concerns that this person is actively using substances. - Having a history of prior violence or intimate partner violence in the home. - Provider concern regarding instability or lack of information about home safety. - Not actively parenting an infant under 12 months of age |
Country | Name | City | State |
---|---|---|---|
United States | Entre Familia Residential Treatment Program | Mattapan | Massachusetts |
United States | New Day Residential Treatment Program | Somerville | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Massachusetts General Hospital |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Recruitment and Enrollment | Total number of individuals approached, consented, and enrolled in the study | Through study completion up to 3 months | |
Primary | Study Feasibility | Count of total number individuals completing intervention and retained through study follow up | Through three months following intervention period | |
Primary | Study Acceptability | Feedback in semi-structured interviews with participants and key stakeholders | Through three months following intervention period | |
Secondary | Maternal sleep quantity | Measurement of total nightly sleep using actigraphy device | Through three months following intervention | |
Secondary | Ability to fall asleep | Insomnia Sleep Index (Measured on a scale of 0-28) | Through three months following intervention | |
Secondary | Sleep quality | Single Item Sleep Quality Scale; | Through three months following intervention | |
Secondary | Postpartum Sleep Quality | Postpartum Sleep Quality Scale | Through three months following intervention | |
Secondary | Maternal mental health - Depression | Patient Health Questionnaire-8 | Through three months following intervention | |
Secondary | Maternal mental health - Anxiety | General Anxiety Disorder-7 | Through three months following intervention | |
Secondary | Medication for Addiction Treatment Retention | Continuation of medication for addiction treatment | Through three months following intervention | |
Secondary | Substance use treatment retention | Retention in residential treatment program | Through three months following intervention | |
Secondary | Recovery Capitol | Brief Assessment of Recovery Capitol (BARC-10) | Through three months following intervention | |
Secondary | Parental stress | Parenting Stress Index | Through three months following intervention | |
Secondary | Parental bonding | Postpartum Bonding Questionnaire; | Through three months following intervention | |
Secondary | Parental self-efficacy | Perceived Parenting Self-Efficacy Questionnaire | Through three months following intervention | |
Secondary | Social Support | Postpartum Social Support Scale | Through three months following intervention | |
Secondary | Unnecessary unscheduled healthcare utilization | ED and Urgent care visits attended | Through three months following intervention | |
Secondary | Filings for child abuse/neglect | 51A-filings for child abuse or neglect to MA DCF | Through three months following intervention |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06021431 -
Virtual Reality Cognitive-Affective Training for Opioid Use Disorder- A Phase 2 RCT
|
N/A | |
Completed |
NCT06266572 -
Overcoming Stigma and Improving Outcomes for SUDs Through Education, Engagement, and Empowerment
|
Phase 1 | |
Recruiting |
NCT05037682 -
Pain and Opioid Management in Older Adults
|
N/A | |
Completed |
NCT06200740 -
Remotely Observed Methadone Evaluation
|
N/A | |
Not yet recruiting |
NCT06441604 -
Extended-release Buprenorphine as a Novel Low-dose Induction Strategy
|
Phase 2 | |
Recruiting |
NCT06028126 -
Superficial Parasternal Intercostal Plane Block in Cardiac Surgery Trial
|
N/A | |
Completed |
NCT02440256 -
Expanded HIV Care in Opioid Substitution Treatment (EHOST) Trial
|
N/A | |
Completed |
NCT02593474 -
Medication-Assisted Treatment for Youth With Substance Use Disorders
|
Phase 1 | |
Completed |
NCT02559973 -
Pharmacokinetics, Safety, and Tolerability of Depot Buprenorphine at Three Different Molecular Weights in Treatment-Seeking Subjects With Opioid Use Disorder
|
Phase 1 | |
Completed |
NCT05587998 -
A Study to Assess the Effect of AZD4041 on Respiratory Drive in Recreational Opioid Users.
|
Phase 1 | |
Terminated |
NCT04577144 -
An Observational Study of Environmental and Socioeconomic Factors in Opioid Recovery - Long Term
|
||
Recruiting |
NCT06001437 -
Following Outcomes Remotely Within Addiction Recovery Domains
|
||
Recruiting |
NCT05976646 -
Phase Ib/2a Drug-drug Interaction Study of a Combination of 45mg Dextromethorphan With 105 mg Bupropion
|
Phase 1/Phase 2 | |
Completed |
NCT05546229 -
Assessment of Methadone and Buprenorphine in Interstitial Fluid
|
||
Not yet recruiting |
NCT06416020 -
Integrating MOUD in African American Community Settings (Better Together)
|
N/A | |
Not yet recruiting |
NCT06104280 -
Medications for Opioid Use Disorder Photosensitive Retinal Ganglion Cell Function, Sleep, and Circadian Rhythms: Implications for Treatment
|
N/A | |
Recruiting |
NCT06206291 -
Cannabidiol for Opioid Addiction
|
Phase 2 | |
Completed |
NCT05552040 -
START NOW in the Treatment of Opioid Addicted Individuals
|
N/A | |
Recruiting |
NCT05459922 -
Adjunctive Bright Light Therapy for Opioid Use Disorder
|
N/A | |
Recruiting |
NCT05343169 -
Community-based Education, Navigation, and Support Intervention for Military Veterans
|
N/A |